Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

SIGA vs MRK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRK Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 9–1 Matrix Metrics)

MRK Overall Winner 6-Pillar Tally: SIGA 2 – 4 MRK Matrix Metrics: SIGA 1 – 9 MRK

As of Nov 19, 2026, Merck & Co., Inc. (MRK) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin), whereas MRK carries 50.8/100 (HOLD) at $132.81 (14.8x Forward P/E, 35.2% operating margin).

  • Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile MRK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SIGA vs MRK
SIGA NASDAQ
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.65
-5.36% 1D
Market Cap $187.9M
TTM Revenue $52M
Forward P/E 2.5x
Beta / 30D Vol 0.75β · 65% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.6%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $3.02 · SMA50: $3.14
MRK NYSE Head-to-Head Winner
Merck & Co., Inc.
Pharmaceutical Preparations
$132.81
-3.61% 1D
Market Cap $339.7B
TTM Revenue $67.4B
Forward P/E 14.8x
Beta / 30D Vol 0.27β · 34% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.7%), weak momentum, RSI 32
RSI-14: 32.2 · SMA20: $144.93 · SMA50: $145.48

6-Pillar Scorecard Institutional Category Breakdown (SIGA 2 – 4 MRK)

Columns: Metric · SIGA · MRK
1. Valuation Multiples SIGA
Forward P/E 2.5x 14.8x
Trailing P/E N/M 139.2x
PEG Ratio 3.37x 3.47x
EV / Revenue 1.4x 5.7x
2. Growth & Scale MRK
Revenue Growth (YoY) -49.7% +4.7%
Earnings Growth (YoY) -65.3% -12.0%
TTM Revenue (USD) $52M $67.4B
Market Cap $187.9M $339.7B
3. Profitability & Quality MRK
Gross Margin 23.4% 75.2%
Operating Margin -14.2% 35.2%
Net Profit Margin 1.3% 3.6%
Return on Equity (ROE) 0.4% 5.1%
4. Balance Sheet & Cash Flow MRK
Cash Generation (TTM) -$12M $14.7B
Cash Flow Margin -22.1% 21.9%
Net Cash / Leverage $116M Net Cash $44.2B Net Debt (1.20x D/E)
Dividend Yield None (0.00%) 2.34%
5. Options & Positioning SIGA
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 81.4% (8th %ile) 30.6% (28th %ile)
Put/Call OI Skew 0.04x (Call-Skewed) 0.80x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat MRK
OpEx & R&D Intensity 37.6% of Rev ($20M) 40.0% of Rev ($27.0B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SIGA (1) vs MRK (9)
Institutional Metric SIGA MRK Criterion Row Edge
Market Capitalization
Scale
$187.9M $339.7B Larger Scale MRK
Trailing P/E Ratio
Valuation
N/M 139.2x Lower Multiple MRK
Forward P/E Ratio
Valuation
2.5x 14.8x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
-49.7% +4.7% Higher Growth MRK
Operating Margin (TTM)
Profitability
-14.2% 35.2% Higher Margin MRK
Net Profit Margin
Profitability
1.3% 3.6% Higher Margin MRK
Return on Equity (ROE)
Capital Efficiency
0.4% 5.1% Higher ROE MRK
52-Week Range Position
Momentum
3% ($3–$7) 63% ($92–$157) Stronger Trend MRK
Beta / 30D Volatility
Risk Regime
0.75β · 65% Vol 0.27β · 34% Vol Lower Realized Risk MRK
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 50.8 / 100 (HOLD) Higher Composite MRK
Trailing 12M Revenue (USD)
Operating Scale
$52M $67.4B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% 75.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.37x PEG · 1.4x EV/Rev 3.47x PEG · 5.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($116M Net Cash) $14.7B ($44.2B Net Debt (1.20x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRK +3.67 pp
SIGA: -15.06% · MRK: -11.39%
3M Horizon SIGA +0.11 pp
SIGA: -12.83% · MRK: -12.94%
6M Horizon MRK +58.35 pp
SIGA: -43.74% · MRK: +14.61%
1Y Horizon MRK +93.34 pp
SIGA: -55.61% · MRK: +37.73%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SIGA Revenue MRK Revenue SIGA Op. Margin MRK Op. Margin Margin Leader
FY2018 $480M $42.3B 74.4% 14.7% SIGA
FY2019 $30M $39.1B -8.7% 25.2% MRK
FY2020 $120M $41.5B 67.6% 17.0% SIGA
FY2021 $130M $48.7B 66.7% 26.8% SIGA
FY2022 $110M $59.3B 38.5% 24.5% SIGA
FY2023 $140M $60.1B 59.8% 0.6% SIGA
FY2024 $140M $64.2B 50.4% 26.7% SIGA
FY2025 $90M $65.0B 25.1% 28.1% MRK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SIGA CONSOLIDATION
33d in phase · OBV DISTRIBUTION
Current IV 81.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRK CONSOLIDATION
61d in phase · OBV DISTRIBUTION
Current IV 30.6%
IV Percentile 28th %ile
Put/Call OI Skew 0.80x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $144.46 · IV 31.1%

MRK Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($14,446)

Compare $14,446 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 31.1% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $145 / $155 Bull Call Spread

Buy 1x $145C · Sell 1x $155C · 31d

Net Entry $340 Debit
T+5d @ +5% Move +$221 (+65%)
Max Risk / Buffer $340 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $135 / $125 Bull Put Spread

Sell 1x $135P · Buy 1x $125P · 31d

Net Entry $149 Credit
Max Credit / Yield +$149 (+17.5% RoM)
Max Risk / Buffer -7.6% Cushion ($851 Mgn)
5d Edge & Liquidity 78% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq B

Asymmetric 1x1x1 ($145C + $143/$130P)

+1x 17d $143P · -1x 59d $130P · +1x 31d $145C

Net Entry $504 Debit
T+5d @ +5% Move +$343 (+16.1% RoM)
Max Risk / Buffer -10.0% Put Cushion ($2,125 Mgn)
5d Edge & Liquidity 9.9x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published
MRK Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $339.7B market capitalization and 35.2% operating margin.
OpEx & R&D Reinvestment 40.0% of Rev ($27.0B)
90D Engineering Disclosures 0 Published

Investor FAQ SIGA vs MRK Key Questions & Quantitative Answers

As of Nov 19, 2026, Merck & Co., Inc. (MRK) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin), whereas MRK carries 50.8/100 (HOLD) at $132.81 (14.8x Forward P/E, 35.2% operating margin). Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile MRK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRK leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with MRK at +4.7% YoY revenue growth and -12.0% YoY earnings growth on $67.4B TTM revenue (75.2% gross margin, 35.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIGA cumulative revenue shifted -81.2% while MRK shifted +53.7%. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus 40.0% of Rev ($27.0B) (0 disclosures) for MRK.

SIGA screens cheaper on headline valuation multiples. SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas MRK trades at 14.8x Forward P/E, 139.2x Trailing P/E, 3.47x PEG, and 5.7x EV/Revenue (21.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus MRK (5.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk). By comparison, MRK carries 30.6% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.80x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 34% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.